Botanix Announces BTX 1503 Data and Progression to Phase 3
Filed with ASX · · 7 pages · English
Watch Botanix Pharmaceuticals' latest callBotanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call · Replay · Mar 2Read the transcript of Botanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings CallBotanix Pharmaceuticals Limited on 6ix
In the deck
Story so far
Earlier from Botanix Pharmaceuticals
- BOT Receives Grant for Synthetic Cannabidiol Analog Program
- Botanix announces new clinical program to target rosacea
- Appendix 4E and Annual Report
- Botanix $40 Million US Lead Placement and Management Update
- Botanix Antimicrobial Platform Addresses Global Threat
Later from Botanix Pharmaceuticals
- Botanix Announces De-scheduling of Synthetic CBD
- Botanix Initiates BTX 1702 Rosacea Study
- Antimicrobial Platform Update and Launch of BTX 1801 Study
- Botanix Announces Top Line BTX 1204 Atopic Dermatitis Data
- Botanix Provides Update on Development Activities
Follow Botanix Pharmaceuticals into a list and get an email when it puts out news.
Follow Botanix Pharmaceuticals